secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001193125-25-119506
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx reports 97% ORR and 68% CR/sCR in Phase 2 anito-cel study for RRMM
--------------------------------------------------------------------------

- Phase 2 iMMagine-1 (117 patients) showed 97% ORR and 68% CR/sCR at median 12.6 months follow-up.
- No delayed neurotoxicities (Parkinsonism, cranial nerve palsies, Guillain-Barré) or immune-mediated enterocolitis.
- 12-month PFS rate 78.8%, OS rate 95.2%; median PFS and OS not reached.
- Data to be presented at EHA2025 on June 14; commercial launch with Kite planned for 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312525119506/0001193125-25-119506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312525119506/d941498d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-119506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer